diabetes
The company reported a net profit of DKK 25.41 billion (€3.404 billion), up from DKK 19.81 billion (€2.654 billion) in the same period last year and surpassing the DKK 23.09 billion (€3.093 billion) anticipated by analysts. Earnings per share (EPS) also rose to DKK 5.68 (€0.76) from DKK 4.39 (€0.589) a year prior, indicating a robust 8.75% surprise over market expectations. Sales for the quarter reached DKK 65.35 billion (€8.747 billion), a 22% increase from DKK 53.37 billion (€7.135 billion) a year ago, outperforming the DKK 63.43 billion (€8.490 billion) forecast by analysts. Weight-loss dru...
Euronews (English)
Scientists say stroke, diabetic nerve damage, and dementia are making neurological diseases the biggest cause of ill health globally. According to a recent study00038-3/fulltext#%20) published in the journal Lancet Neurology, researchers from the University of Washington in the US and their international collaborators say neurological conditions now affect 3.4 billion people worldwide. The global counts for total nervous system health loss have increased by 18.2 per cent from 375 million in 1990 to 443 million disability-adjusted life years (DALYs) in 2021. Meet 'Viv,' the AI companion helping...
Euronews (English)
Danish pharmaceutical powerhouse Novo Nordisk has emerged as one of the standout performers among European mega-cap stocks in the early months of this year, boasting a robust 25% surge year to date. This performance further cemented Novo Nordisk's status as the largest European company by market capitalisation, reaching almost €550 billion and outpacing the market value of Tesla. Over the past year, the Danish pharma titan has seen its price jump by 80%, a rate of increase unmatched by any other European company valued at €100 billion or more. Novo Nordisk's growth driver: Weight-loss drug Weg...
Euronews (English)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら